CEO Krishna Vaddi was paid $1,348,000 in fiscal year 2025, ↓ down 42.1% from fiscal year 2024 (SEC filing 0001193125-26-191532 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,348,000 ↓ Krishna Vaddi total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | 99.6% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
PRLD's next annual pay disclosure, estimated April 29, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Krishna Vaddi | $615,441 | $0 | $0 | $412,744 | $309,465 | $0 | $10,350 | $1,348,000 |
| Chief Executive Officer | ||||||||
| Bryant Lim | 477,500 | 0 | 0 | 166,347 | 193,200 | 0 | 10,350 | 847,397 |
| Chief Legal Officer, Corporate Secretary, and Chief Financial Officer | ||||||||
| Peggy Scherle | 473,416 | 0 | 0 | 145,523 | 190,440 | 0 | 10,350 | 819,729 |
| Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Krishna Vaddi | $1,348,000 | $2,327,471 | — | ↓ −979,471 |
| Bryant Lim | 847,397 | 1,202,912 | — | ↓ −355,515 |
| Peggy Scherle | 819,729 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Prelude Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper PRLD reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses PRLD in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PRLD in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Peggy Scherle | Chief Scientific Officer | $819,729 |
| Bryant Lim | CFO | $847,397 |
| Krishna Vaddi | CEO | $1,348,000 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| David P. Bonita | Independent Director | $86,033 |
| Katina Dorton | Independent Director | $77,564 |
| Martin Babler | Independent Director | $78,533 |
| Paul A. Friedman | Independent Director | $102,533 |
| Paul Scherer | Independent Director | $81,566 |
| Victor Sandor | Independent Director | $194,528 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Peggy A. Scherle, Ph. D. | OPTION | 2025-02-04 | — | — | 175,000 | — | $145,523 |
| Bryant Lim | OPTION | 2025-02-04 | — | — | 200,000 | — | 166,347 |
| Krishna Vaddi, Ph.D. | OPTION | 2025-02-04 | — | — | 496,000 | — | 412,744 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Peggy A. Scherle, Ph. D. | $0 | $0 | $145,523 | 0.0% |
| Bryant Lim | 0 | 0 | 166,347 | 0.0% |
| Krishna Vaddi, Ph.D. | 0 | 0 | 412,744 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Krishna Vaddi | Option | 96,250 | 7.2 | — |
| Krishna Vaddi | RSU | 12,969 | — | 0 |
| Krishna Vaddi | Option | 13,663 | 10.58 | — |
| Krishna Vaddi | Option | 239,063 | 4.59 | — |
| Krishna Vaddi | Option | 496,000 | 1.11 | — |
| Peggy Scherle | Option | 4,167 | 10.58 | — |
| Bryant Lim | Option | 84,375 | 4.59 | — |
| Peggy Scherle | Option | 39,375 | 7.2 | — |
| Peggy Scherle | Option | 84,375 | 4.59 | — |
| Peggy Scherle | Option | 175,000 | 1.11 | — |
| Bryant Lim | Option | 78,125 | 5.93 | — |
| Bryant Lim | Option | 15,105 | 3.86 | — |
| Bryant Lim | Option | 200,000 | 1.11 | — |
The Company's compensation program is designed to attract, retain, and motivate executive officers by providing a balanced mix of base salary, annual cash incentives, and long-term equity awards. Equity-based compensation is viewed as a critical component to align the interests of executives with those of shareholders, rewarding past performance and creating incentives to meet long-term objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 26,869,142 | 107,500 | 76,115 | 99.6% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-09 | 99.6%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Victor SandorIndependent · Nominating and Corporate Governance (Chair) | $46,000 | — | $148,528 | — | — | $194,528 |
| Paul A. FriedmanIndependent · Nominating and Corporate Governance | 74,000 | — | 28,533 | — | — | 102,533 |
| David P. BonitaIndependent · Compensation (Chair) · Audit | 57,500 | — | 28,533 | — | — | 86,033 |
| Paul SchererIndependent · Nominating and Corporate Governance · Compensation | 24,500 | — | 57,066 | — | — | 81,566 |
| Martin BablerIndependent · Audit · Compensation | 50,000 | — | 28,533 | — | — | 78,533 |
| Katina DortonIndependent · Audit (Chair) | 11,301 | — | 66,263 | — | — | 77,564 |
| Krishna VaddiEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $263,301 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $263,301 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Prelude Therapeutics | 2025 | Krishna Vaddi | $615,441 | $0 | $412,744 | $309,465 | $1,348,000 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Krishna Vaddi | DEF 14A | 2026-04-29 | 0001193125-26-191532 | Section “Executive Compensation”. As printed: 1,348,000. Filing ↗machine: span 557496–557505 |
| 2 | Section 01, Bryant Lim | DEF 14A | 2026-04-29 | 0001193125-26-191532 | Section “Executive Compensation”. As printed: 847,397. Filing ↗machine: span 576113–576120 |
| 3 | Section 01, Peggy Scherle | DEF 14A | 2026-04-29 | 0001193125-26-191532 | Section “Executive Compensation”. As printed: 819,729. Filing ↗machine: span 566883–566890 |
| 4 | Section 03, Peggy A. Scherle, Ph. D. OPTION | DEF 14A | 1900-01-01 | 0001193125-26-191532 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 618997–619004 |
| 5 | Section 03, Bryant Lim OPTION | DEF 14A | 1900-01-01 | 0001193125-26-191532 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 626949–626956 |
| 6 | Section 03, Krishna Vaddi, Ph.D. OPTION | DEF 14A | 1900-01-01 | 0001193125-26-191532 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 611031–611038 |
| 7 | Section 08, Victor Sandor | DEF 14A | 2026-04-29 | 0001193125-26-191532 | Section “Director Compensation”. As printed: 194,528. Filing ↗machine: span 315298–315507 |
| 8 | Section 08, Paul A. Friedman | DEF 14A | 2026-04-29 | 0001193125-26-191532 | Section “Director Compensation”. As printed: 102,533. Filing ↗machine: span 310648–310857 |
| 9 | Section 08, David P. Bonita | DEF 14A | 2026-04-29 | 0001193125-26-191532 | Section “Director Compensation”. As printed: 86,033. Filing ↗machine: span 301339–301547 |
| 10 | Section 08, Paul Scherer | DEF 14A | 2026-04-29 | 0001193125-26-191532 | Section “Director Compensation”. As printed: 81,566. Filing ↗machine: span 306072–306280 |
| 11 | Section 08, Martin Babler | DEF 14A | 2026-04-29 | 0001193125-26-191532 | Section “Director Compensation”. As printed: 78,533. Filing ↗machine: span 292025–292233 |
| 12 | Section 08, Katina Dorton | DEF 14A | 2026-04-29 | 0001193125-26-191532 | Section “Director Compensation”. As printed: 77,564. Filing ↗machine: span 296603–296811 |
| 13 | Section 08, Krishna Vaddi | DEF 14A | 2026-04-29 | 0001193125-26-191532 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 06, 2026 vote | Form 8-K | 2026-06-10 | 0001193125-26-265835 | Item 5.07 · say-on-pay result. As reported: 99.6% (votes for as printed: 26,869,142). Filing ↗ |
| 15 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 16 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 17 | Section 09b board cost (computed) | Computed | — | — | Cash 263,301 + equity 0 + all other 0 = 263,301, summed across the director compensation table rows.machine: formula: Σ = 263,301 |
| 18 | Prelude Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191532 | CEO total compensation as printed in Prelude Therapeutics's own proxy. As printed: 1,348,000. Filing ↗machine: span 557496–557505 |